Cyro-Cell - Therapie mit Stammzellen - 500 Beiträge pro Seite

[JoeUp]

Thread: Stammzellentherapie - erste Erfolge !!!

[pinebeach]

ist definitiv einen Blick wert!

[JoeUp]

CRYO-CELL Selects Lulla Smith to Design Premium for American Baby Sampling Program Luxury Brand Baby Linen Designer Creates Exclusive CRYO-CELL Moses Basket

CLEARWATER, Fla., Jul 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- In April
2004, CRYO- CELL International, Inc. (OTC Bulletin Board: CCEL) (the "Company")
previously announced its category exclusive participation in American Baby`s
Prenate Elite(TM) 1st Trimester sampling program. Today, the Company announced
that expectant mothers receiving the samples of Prenate Elite(TM) prenatal
vitamins will be eligible to receive a complimentary Moses Basket ensemble
designed by Lulla Smith(TM) when enrolling in CRYO-CELL`s U-Cord(R) Stem Cell
Preservation Service.

(Photo: http://www.newscom.com/cgi-bin/prnh/20040706/FLTU020 )

Physicians and other prenatal care providers will begin receiving sample boxes
of Prenate Elite(TM) prenatal vitamins which include CRYO-CELL`s offer beginning
in mid-July 2004. Approximately 800,000 vitamin samples will be distributed each
quarter; CRYO-CELL`s commitment is to participate in the sampling program for
five consecutive quarters, with a first right of refusal to continue thereafter.
The CRYO-CELL Moses Basket by Lulla Smith(TM) is the first premium selected by
CRYO-CELL for this sampling program. The Company will begin distributing the
gift to parents enrolling in the U-Cord(R) program as a result of this offer
starting in July.

With a retail value of $450, the Lulla Smith(TM) design exclusive to CRYO- CELL
will provide parents with a lovely and highly coveted keepsake for their newborn
child. The Moses Basket ensemble is complete with skirting, linens, a coverlet
and a decorative pillow, all made from the finest Dupioni silk and Egyptian
cotton. Lulla Smith has recently enjoyed publicity in People magazine and other
periodicals as the creator of crib linens for the daughter of celebrities
Courteney Cox and David Arquette. Moses baskets have enjoyed recent popularity
first as a day bed for infants, then as a beautiful display for toys and gifts.

"I`m very enthusiastic about the services that CRYO-CELL provides and proud to
be collaborating with them on such an exciting campaign," stated Carol Smith,
proprietor of Lulla Smith, LLC. "We at Lulla Smith pride ourselves on
high-quality, exquisitely designed baby bedding, bassinets and moses baskets.
The partnership between Lulla Smith and CRYO-CELL will afford expectant parents
the opportunity to take advantage of two premium brands."

"We are very pleased to partner with Lulla Smith(TM) to offer an exclusively
designed CRYO-CELL heirloom gift to parents who enroll through the American Baby
Sampling Program," commented Mercedes Walton, Chairman and interim CEO. "As the
premiere designer of upscale baby bedding and linens, Lulla Smith(TM) represents
impeccable quality with both practical and treasured value to parents. The
limited-edition CRYO-CELL Moses Basket ensemble by Lulla Smith(TM) will serve as
an exquisite and compelling symbol to families enrolling through the Prenate
Elite(TM) 1st Trimester sampling program of the practical and treasured value of
preserving their newborn`s cord blood stem cells."

About CRYO-CELL International, Inc.

Based in Clearwater, Florida, CRYO-CELL is the world`s largest U-Cord(R) stem
cell banking firm, offering high-quality cord blood preservation exclusively for
the benefit of newborn babies and possibly other members of their family.
CRYO-CELL is accredited by the American Association of Blood Banks (AABB).

CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol ... CCEL.
Expectant parents or healthcare professionals may call 1-800-STOR-CELL
(1-800-786-7235) or visit http://www.CRYO-CELL.com.

About Lulla Smith, LLC

Based in Camden, Maine, Lulla Smith(TM) is a designer of luxury baby linens
distributed nationally through high-end baby boutiques and e-commerce outlets.
She specializes in handmade linens for bassinets, moses baskets and cribs. Lulla
Smith linens are made from the most opulent silks and finest cottons. To contact
Lulla Smith call 207-230-0832 or visit http://www.lullasmith.com.

Forward-Looking Statement

[JoeUp]

http://www.babybox.com/mosesbaskets1.html

[JoeUp]

www.hot-stocks-investor.de/

Mit gleich zwei Paukenschlägen wartete in den letzten Tagen unser Pick im Biotech-Play CRYO CELL auf! Nicht, dass die Gesellschaftnicht auch schon in den Vorwochen mit einer ausserordentlich starkenPerformance für Aufsehen gesorgt hatte ? es ging noch besser. Als erstes legte CRYO CELL die Zahlen vom Q 2 per 31. Mai auf den Tischund bestätigte auf voller Linie unsere wiederholten Empfehlung, demTitel Zeit zu lassen und die Korrektur einfach laufen zu lassen. Für alles andere war es dann nämlich auf einen Schlag zu spät: Um 38%legten die Titel nach der Vorlage der Quartalszahlen zu und bautendiesen Schub weiter auf gut USD 2 aus! Aus gutem Grund:

Die Umsätze betrugen USD 3.2 Mio., was fast einer exakten Verdoppelung zum Vorjahr entsprach. CRYO CELL berichtete, dass sowohl eine signifikante Zunahme an neuen Kunden als auch die Durchsetzbarkeit von Preiserhöhungen am Markt dieses Ergebnis ermöglicht haben. Und das schlug sich auch voll auf die Ertragsrechnung nieder: Der Net Income wurde für das Q 2 mit USD 608`000 ermittelt ? ein Rekordwert für die zuvor jahrelang im Minus operierenden Gesellschaft. Allein im entsprechenden Vorjahresquartal hatte man noch einen Verlust von USD 1.3 Mio. verbucht. In der 6-Monats-Bilanz schreibt man damit ein Nettoergebnis von USD 823`000 - und das mit schwarzer Tinte! Die heftige Kursreaktion ist damit mehr als gerechtfertigt. Was Sie hier gesehen haben, könnte der Startschuss für die anstehende nachhaltige Neubewertung des Titels sein. Sie wissen: Vor nicht einmal ganz 2 Jahren wurden für den Titel noch Kurse von weit über USD 10 bezahlt, als CRYO CELL noch nicht mehr als ein spannendes Business Konzept mit tiefroter Bilanz war. Wir bleiben für den Titel, den wir auch als Core-Position in unserem Musterdepot mit glänzendem Erfolg spielen, klar auf ?strong buy? und sehen uns darin durch die brandaktuellen News von gestern bestätigt:

CRYO CELL meldete gestern die Teilnahme am American Baby`s Prenate Elite(TM)-Programm. In diesem Programm werden angehenden Familien besondere Service- und Produktdienstleistungen als Give-away-Pakete gesponsert, u.a. bestimmte Vitaminkuren für die Schwangerschaftsphase. In diesem Geschenk-Paket, für das CRYO CELL ein wertvolles Start- package einer exklusiv für diesen Zweck designten Linie von hoch- wertiger Badykleidung, Bettwäsche, einer Wolldecke etc. beisteuert, kann die Gesellschaft jetzt ihr Angebot für eine Stammzellen- Archivierung präsentieren und damit eine so gezielte und spezifische Werbung machen, wie es besser fast nicht geht. Die Überlegung, dass die Investition in dieses Geschenkpaket gut investiert sein dürfte, könnte in der Tat aufgehen. Der Start erfolgt jetzt im Juli und wird zunächst für 5 Quartale laufen. Wir sind gespannt, wie sich der Newsflow über die Erfolge in den kommenden Monaten darstellen werden! Der Markt zeigt jedenfalls, wie gut diese Nachricht aufgenommen wurde. Da legten CRYO CELL am Donnerstag mit einem Plus von 15,3% gegen das grottenschwache Umfeld auf neue Jahreshochs von USD 2,19 zu! Bleiben Sie hier unbedingt am Ball und geben Sie kein Stück aus der Hand! Nachzüglern empfehlen wir, jeden Taucher des Kurses in Pendelbewegungen in Richtung USD 2 oder knapp unter diese Linie sofort zum Hinterhergehen zu nutzen und stellen CRYO CELL (WKN 923 368) deshalb heute nochmals mit diesen Abstauberlimits als Top Tipp des Tages zum Kauf!

[Rentner]

Joe, ich bitte dich. Was soll ich denn mit einer Firma, die Erfolg bzw. ein Produkt vorzuweisen hat? Ich setze da doch lieber auf UPGD, wo ich erst seit Jahren auf ein Produkt warte. Die Chancen Geld zu verlieren (ev. auch zu gewinnen) sind doch da viieel besser.

[JoeUp]

http://www.nasdaq.com/aspx/RevenueEPSSummary.aspx?mode=&kin…

http://www.cryo-cell.com/inv_pressrelease.asp?ID=150

October 4, 2004
CRYO-CELL International, Inc. Reports Results For Third Quarter 2004
<http://www.cryo-cell.com/images/greenpixel.gif>

Company Reports Net Income, Increased Revenues, Higher Gross Margins, and Strong Cash Position

TREND OF SOLID PERFORMANCE CONTINUES AS STRATEGIC PLAN TO ACHIEVE TRANSFORMATIONAL SUCCESS REMAINS WELL ON TRACK

Clearwater, FL ? October 4, 2004 - CRYO-CELL International, Inc. (OTC Bulletin Board Symbol: CCEL) (the "Company") today announced consolidated revenues of approximately $3.2 million for the third quarter ended August 31, 2004, compared to approximately $2.0 million for the third quarter of fiscal 2003. The 59% revenue increase over the same 2003 period is primarily attributable to an increase in recurring annual storage revenues and the effects of successfully implemented price increases during 2004 for newly enrolling clients.

Net income in the third quarter of 2004 was approximately $1.9 million, compared to a net loss of approximately $889,000 in the third quarter of 2003. Net income in the third quarter of 2004 included approximately $1.6 million from the reversal of all prior accruals with respect to the PharmaStem litigation, as a result of the favorable ruling by the Court on post trial motions in that case. The remaining approximately $300,000 in net income was principally due to increased revenues and gross profits compared to 2003 levels. The Company?s gross margin increased to 73% of revenue in the third quarter of 2004 from 68% in the 2003 period. The gross margin improvement is a result of increased revenues due to price increases combined with relatively fixed costs as described above. As of August 31, 2004, the Company had $4.2 million in available cash and cash equivalents and no long-term debt. Also, as a result of the Court?s favorable ruling in the PharmaStem litigation, the Company will obtain approximately $958,000 that was being held in an escrow account per the original jury verdict. The Company expects the monies to be returned during the fourth quarter 2004.

For the nine-month period ended August 31, 2004, the Company?s revenues were approximately $9.0 million, compared to approximately $5.1 million for the nine-month period ended August 31, 2003. The 77% revenue increase over the same 2003 period is primarily attributable to an increase in recurring annual storage revenues and the effects of successfully implemented price increases during 2004 for newly enrolling clients. Net income for the nine-month period ended August 31, 2004 was approximately $2.7 million, compared to a net loss of approximately $3.1 million in the 2003 period. As described above, net income for the 2004 period included $1.6 million from the reversal of all prior accruals related to the PharmaStem litigation during the third quarter of 2004. The Company?s remaining $1.1 million in net income was due to increased revenues as described above. The Company?s gross margin increased to 75% of revenue in the first nine months of 2004 from 62% in the 2003 period. The 13% gross margin improvement is a result of increased revenues due to price increases combined with relatively fixed costs as described above.

"We are very pleased with CRYO-CELL?s continuing solid performance throughout the third quarter and with our progress towards operational expansion and strategic market development," commented Mercedes Walton, Chairman and interim CEO. ?We are also encouraged by the recent favorable Court ruling on post trial motions in the PharmaStem matter which determined that the jury`s earlier verdict of infringement was, according to the Court?s opinion, "against the great weight of the evidence". This ruling is a positive development for CRYO-CELL, the practitioner community and the families we serve and contributed positively to third quarter results with the reversal of approximately $1.6 million in prior accruals. As a result of this ruling, we expect approximately $958,000 held in escrow to be returned to the Company in the fourth quarter. Ultimately, we expect both of the patents will be invalidated, and PharmaStem?s present claims will be unenforceable.?

?The Company has also made significant progress in controlling our costs on a year-to-date basis. Notwithstanding anticipated quarterly fluctuations due to planned increases in marketing and sales spending, along with pending litigation matters, we expect to continue to tightly manage expense while maximizing shareholder profitability.? Ms. Walton continued, ?CRYO-CELL is well on track with our strategic plan to achieve transformational success.?

[JoeUp]

http://www.cryo-cell.com/inv_pressrelease.asp?ID=151

October 6, 2004
CRYO-CELL International, Inc. Expands To India

Asia CRYO-CELL Private Limited to Establish the U-Cord®;Program in One of the World?s Largest Birth Markets

Clearwater, FL ? October 6, 2004 - CRYO-CELL International, Inc. (OTC Bulletin Board Symbol: CCEL) (the ?Company?) today announced that it has signed a definitive License and Royalty Agreement with Asia CRYO-CELL Private Limited, a newly formed Indian company, to establish and market its industry-leading U-Cord®; program in India. Asia CRYO-CELL Private Limited (ACCPL) also has an option to expand into Singapore and Malaysia. The 20-year agreement, with renewal provisions, provides for the transfer of the Company?s technology, know-how and quality systems to ACCPL in return for up-front license fees and on-going royalties on ACCPL?s processing and storage revenues. ACCPL?s administrative offices and newly constructed laboratory and storage facility will be headquartered in the outskirts of Chennai, with anticipation that sales and service offices will be established in major cities throughout India. Indian government approval is expected shortly.

India is the seventh largest and second most populous country in the world with approximately 20 million births per year representing one of the largest birth markets in the world. A recent series of ambitious economic reforms aimed at deregulating the country and stimulating foreign investment have moved India to the forefront of the rapidly growing Asia Pacific region, creating major emerging market opportunities.

While Asia CRYO-CELL Private Limited is a newly-formed company, its start-up funding is guaranteed by Abusha Investment & Management Services Private Limited. ACCPL?s Vice Chairman and Chief Executive Officer is also the principal promoter of Shasun Chemicals and Drugs Limited, a $60 million Indian company that is the world?s largest manufacturer of the active pharmaceutical ingredient ibuprofen. Therefore, the new company will have access to know-how in Good Manufacturing Practices (cGMP) techniques and has strong competencies and abilities in research science, bio-technology and quality systems.

?We are very pleased to be working with a partner that is well capitalized and has demonstrated skills, knowledge and professional networks necessary to successfully launch the U-Cord program in India,? stated Mercedes Walton, CRYO-CELL?s Chairman and interim Chief Executive Officer. ?While CRYO-CELL?s predominant focus is to build the domestic market, the strategic synergies and economic potential of the India expansion proposal are decisively compelling at a time when our Company is demonstrating solid performance building on recent revenue growth, increased earnings and enhanced shareholder value. We could not have asked for a more ideally-suited partner to join other successful CRYO-CELL affiliates in Mexico, Central America, and Ecuador.?

S. Abhayakumar agreed, ?We are delighted to be working with the industry leader in cord blood stem cell collection and preservation. Our first mover advantage, combined with our experienced resources, will allow us to establish a significant business, while offering this important new service to the Indian people.?

Asia CRYO-CELL plans to complete its facility construction in time to launch the U-Cord service by year-end 2004. There is a one-year option from that point to expand into Singapore and Malaysia.

About CRYO-CELL International, Inc.
Based in Clearwater, Florida, CRYO-CELL is the world`s largest U-Cord® stem cell banking firm, offering high-quality cord blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. CRYO-CELL is accredited by the American Association of Blood Banks (AABB).

CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.CRYO-CELL.com.

[JoeUp]

http://www.cryo-cell.com/inv_pressrelease.asp?ID=151

October 6, 2004
CRYO-CELL International, Inc. Expands To India

Asia CRYO-CELL Private Limited to Establish the U-Cord®;Program in One of the World?s Largest Birth Markets

Clearwater, FL ? October 6, 2004 - CRYO-CELL International, Inc. (OTC Bulletin Board Symbol: CCEL) (the ?Company?) today announced that it has signed a definitive License and Royalty Agreement with Asia CRYO-CELL Private Limited, a newly formed Indian company, to establish and market its industry-leading U-Cord®; program in India. Asia CRYO-CELL Private Limited (ACCPL) also has an option to expand into Singapore and Malaysia. The 20-year agreement, with renewal provisions, provides for the transfer of the Company?s technology, know-how and quality systems to ACCPL in return for up-front license fees and on-going royalties on ACCPL?s processing and storage revenues. ACCPL?s administrative offices and newly constructed laboratory and storage facility will be headquartered in the outskirts of Chennai, with anticipation that sales and service offices will be established in major cities throughout India. Indian government approval is expected shortly.

India is the seventh largest and second most populous country in the world with approximately 20 million births per year representing one of the largest birth markets in the world. A recent series of ambitious economic reforms aimed at deregulating the country and stimulating foreign investment have moved India to the forefront of the rapidly growing Asia Pacific region, creating major emerging market opportunities.

While Asia CRYO-CELL Private Limited is a newly-formed company, its start-up funding is guaranteed by Abusha Investment & Management Services Private Limited. ACCPL?s Vice Chairman and Chief Executive Officer is also the principal promoter of Shasun Chemicals and Drugs Limited, a $60 million Indian company that is the world?s largest manufacturer of the active pharmaceutical ingredient ibuprofen. Therefore, the new company will have access to know-how in Good Manufacturing Practices (cGMP) techniques and has strong competencies and abilities in research science, bio-technology and quality systems.

?We are very pleased to be working with a partner that is well capitalized and has demonstrated skills, knowledge and professional networks necessary to successfully launch the U-Cord program in India,? stated Mercedes Walton, CRYO-CELL?s Chairman and interim Chief Executive Officer. ?While CRYO-CELL?s predominant focus is to build the domestic market, the strategic synergies and economic potential of the India expansion proposal are decisively compelling at a time when our Company is demonstrating solid performance building on recent revenue growth, increased earnings and enhanced shareholder value. We could not have asked for a more ideally-suited partner to join other successful CRYO-CELL affiliates in Mexico, Central America, and Ecuador.?

S. Abhayakumar agreed, ?We are delighted to be working with the industry leader in cord blood stem cell collection and preservation. Our first mover advantage, combined with our experienced resources, will allow us to establish a significant business, while offering this important new service to the Indian people.?

Asia CRYO-CELL plans to complete its facility construction in time to launch the U-Cord service by year-end 2004. There is a one-year option from that point to expand into Singapore and Malaysia.

About CRYO-CELL International, Inc.
Based in Clearwater, Florida, CRYO-CELL is the world`s largest U-Cord® stem cell banking firm, offering high-quality cord blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. CRYO-CELL is accredited by the American Association of Blood Banks (AABB).

CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.CRYO-CELL.com.

[JoeUp]

http://www.cryo-cell.com/inv_pressrelease.asp?ID=152

October 11, 2004
Breakthrough Research Findings from CRYO-CELL Affiliate and its Collaborators

Compelling Evidence for Potential Future Human Therapeutic Value to Parents Weighing Benefits of Banking Their Newborn?s Cord Blood

Clearwater, FL ? October 11, 2004 - CRYO-CELL International, Inc. (OTC Bulletin Board: CCEL) (the ?Company?) announced today that its affiliate, Saneron CCEL Therapeutics, Inc. (?Saneron CCEL?), in collaboration with its research affiliates, recently published promising results using cord blood stem cells in conjunction with stroke in animal models. In the October issue of American Heart Association?s prestigious journal, Stroke, an article co-published by the Medical College of Georgia (MCG) and the University of South Florida (USF) describes the key findings:

· Stem cells taken from umbilical cord blood, and then given intravenously along with a drug known to temporarily breach the brain`s protective barrier, can dramatically reduce stroke size and damage.
· When used in the first hours and days following a stroke, stroke size decreased by 40 percent and the resulting disability was significantly reduced.
· Dr. Paul R. Sanberg, neuroscientist at the University of South Florida, co-author on the study and co-founder of Saneron CCEL commented, ?This is an important finding because it shows that umbilical cord blood cells do not have to become new brain cells to protect the brain.?

?CRYO-CELL is very pleased to report these exciting research findings from MCG?s and USF?s impressive study efforts?, commented Mercedes Walton, CRYO-CELL?s Chairman and interim CEO. ?We believe that this breakthrough research study that utilized non-controversial cord blood stem cells provides compelling evidence for potential future human therapeutic value. This is an important consideration for parents who are weighing the benefits of banking their newborn?s cord blood. The promise of emerging stem cell research and development is unfolding in extraordinary ways.?

The entire press release can be found at: http://www.eurekalert.org/pub_releases/2004-09/mcog-ucb09240… . CRYO-CELL International, Inc. has approximately 43% equity in Saneron CCEL. The lead researchers are consultants to Saneron CCEL.

About CRYO-CELL International, Inc.
Based in Clearwater, Florida, CRYO-CELL is the world`s largest U-Cord® stem cell banking firm, offering high-quality cord blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. CRYO-CELL is accredited by the American Association of Blood Banks (AABB).
CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit www.CRYO-CELL.com.

About Saneron CCEL Therapeutics, Inc.
Saneron CCEL Therapeutics, Inc. is a biotechnology R&D startup company focused on cell therapy for the early intervention and treatment of several devastating or deadly diseases, which currently lack adequate
treatment options. Saneron CCEL, a University of South Florida spin-out company, is located at the Tampa Bay Technology Incubator. Saneron CCEL is committed to providing readily available, non-controversial stem
cells for cellular therapies and has exclusively licensed patented technology relating to our platform technology of U-CORD-CELL? - Umbilical cord blood, and SERT-CELL? - Sertoli cells.

[JoeUp]

bisher 22 Cent pro Aktie verdient. Mit einem koservativen Faktor 11 ergäbe das den derzeitigen Kurs von ca. 2,40 Dollar.
Sollten im 4. Quartal nochmals 10-15 Cent verdient werden, so ergäbe dies ein Potenzial zum Jahresende von ca. 3,30 bis 3,85 Dollar.

http://www.nasdaq.com/aspx/RevenueEPSSummary.aspx?mode=&kin…

[JoeUp]

SPIEGEL ONLINE - 23. November 2004, 11:31
URL: http://www.spiegel.de/wissenschaft/mensch/0,1518,328591,00.h…

Organe aus dem Bioreaktor

Frankensteins Erben

Von Hanno Charisius

Wenn beim Menschen ein Organ ausfällt, dann muss Ersatz her. Weil Spenderorgane rar sind und zudem häufig Probleme bereiten, arbeiten Wissenschaftler an Organen aus der Retorte. Große Hoffnungen setzen sie in die Rekrutierung von Stammzellen.

[Kunstherz: Vorerst aus Metall und Kunststoffen]
[Großbildansicht]
DPA
Kunstherz: Vorerst aus Metall und Kunststoffen
Ein paar Zellen in den Bioreaktor geben, warten und dann ein frisches Organ aus dem Inkubator ziehen: Nervenstränge, Brüste, Lebern, Zähne, Haut, Augen, ja, einen ganzen Arm - Science-Fiction-Fans ist derartiges längst vertraut. Glaubt man den Gewebekonstrukteuren, dann ist diese Vision schon heute Realität. Knochenscheibchen, Knorpelteile, Hautlappen, Sehnen und Herzklappen gibt es tatsächlich schon zu kaufen, auch wenn die künstlichen Organe vor allem aus Kunststoffen bestehen.

Doch auch an "lebendigen" Ersatzorganen arbeiten die Menschenzüchter: 1907 brachte der Zoologe Ross Harrison kultivierte Nervenzellen dazu, sich zu teilen. In den sechziger Jahren ließen verschiedene Gruppen einzelne Zellen zu einem dichten Rasen auf dem Boden eines Kulturgefäßes wachsen. 1972 brachte Richard Knazek Leberzellen auf Hohlfasern zum Sprießen. 1981 wurde Brandopfern Haut transplantiert, die aus körpereigenen Zellen gezüchtet worden waren.

Tissue Engineering (TE) heißt die Disziplin, die Körperteile aus der Retorte verspricht: Gewebe und Organe auf Bestellung und keine Wartelisten für Organspenden. Es sind Menschen wie Anthony Atala von der Harvard Medical School, die die Vision vom Organ von der Stange entwickelt haben. Wer erinnert sich nicht an die Meldung, dass Forscher ein männliches Geschlechtsteil "mit Gefühl" im Labor gezüchtet haben?

Technology Review
Das M.I.T.-Magazin für Innovation

Dieser leicht gekürzte Text stammt aus der aktuellen Ausgabe von "Technology Review".

<http://www.spiegel.de/static/sys/v6/minipfeil_4C4C4C_6x11.gi… Inhaltsverzeichnis
<http://www.spiegel.de/static/sys/v6/minipfeil_4C4C4C_6x11.gi… Aktuelles Heft bestellen
Immerhin ist Atala geglückt, den Schwellkörper von Kaninchen nachzuzüchten. "Die Äußerungen einzelner Forscher suggerieren, dass das Gebiet viel weiter ist, als es den Tatsachen entspricht", sagt Bärbel Hüsing vom Fraunhofer-Institut für Systemtechnik und Innovationsforschung in Karlsruhe. Aber "man muss noch Jahre, vielleicht Jahrzehnte forschen".

Jedes Organ besteht aus verschiedenen Zelltypen. Alle existierenden TE-Produkte bestehen aus höchstens zwei unterschiedlichen Zelltypen und sind simpel aufgebaut: Haut wächst auf dem Boden von Zellkulturflaschen, Knorpelzellen werden mit Fibrinkleber auf einem bioresorbierbaren Vlies fixiert und dann an die verletzte Stelle transplantiert.

Bei der Zucht ganzer Organe treten noch viele Probleme auf. Man kennt nicht einmal die Mechanismen, wie sich Zellen zu ganzen Organen zusammenfinden. Um ihren Zellkonstrukten dennoch eine Form zu geben, greifen die Gewebezüchter auf vorgefertigte Gerüste aus Polymeren zurück, die man mit Knorpelzellen besiedelt, die dann das Trägermaterial ersetzen, bis schließlich das fertige bioartifizielle Ersatzteil von einem Chirurgen verpflanzt wird.

[Nierentransplantation: Weg zu körpereigenen Organen ist noch lang]
[Großbildansicht]
DPA
Nierentransplantation: Weg zu körpereigenen Organen ist noch lang
Bei größeren Werkstücken stößt diese Technik bislang an Grenzen. Manche Forscher versuchen, natürliches Material zu recyceln. Die Firma Auto-Tissue aus Berlin verwendet Herzklappen von Schweinen, um daraus humanisierte Transplantate zu züchten. Das Münchner Unternehmen Vascular Biotech verwendete bis zum Insolvenzverfahren Mitte 2003 Venen von Spendern als Gerüst für die Neubesiedelung mit Patienten-Zellen.

Ein noch kreativerer Ansatz besteht in einer Abwandlung des so genannten Rapid-Prototyping-Verfahrens. Dabei wird der Druckkopf eines Spezialdruckers mit Zellen und Lösemittel befüllt und spritzt dann schichtweise Zellen in beliebige Formen. An den hannoverschen Leibniz-Forschungsinstituten für Biotechnologie und künstliche Organe wiederum versucht man, Schweinedarm in Luftröhren zu verwandeln. Nach Entfernung der Schweinezellen werden Arterien und Venen mit Epithelzellen besiedelt.

Mit der Wiederverwendung der Blutgefäße des Darmstücks lösen die Hannoveraner eines der größten Probleme: Wenn die Ersatzteile zu groß werden, als dass frische Nährstoffe noch allein aufgrund der Diffusion an die Zellen gelangen könnten, stirbt das Konstrukt von innen heraus. Bei bioartifiziellen Knochenchips mit einem Durchmesser von etwa acht Millimetern, wie sie das Freiburger Unternehmen BioTissue Technologies anbietet, durchziehen feine Gefäße das Transplantat, sobald es fest eingewachsen ist. "Der neue Knochen gibt Signale in die Umgebung ab, die Köperzellen dazu veranlassen, neue Gefäße anzulegen", sagt Jochen Ringe von der Berliner Charité.

[Vorbild Tintenstrahldrucker: Organe Schicht für Schicht aufbauen]
[Großbildansicht]
Nasser Manouchehri
Vorbild Tintenstrahldrucker: Organe Schicht für Schicht aufbauen
Im Labor von Deutschlands TE-Pionier Michael Sittinger sucht Ringe Botenstoffe, die körpereigene Stammzellen dazu bringen, in Gewebe einzuwachsen und sich dort passend zu differenzieren. Auf ein ähnliches Phänomen hofft man bei einer experimentellen Darmrekonstruktion, bei der ein Stück Dünndarm von Zellbestandteilen befreit wird. Zurück bleibt ein Gitternetz, das auf die Wunde im Verdauungstrakt genäht wird. Man hofft, dass Zellen aller typischen Wandschichten in die Matrix einwandern.

Stammzellrekrutierung ist womöglich die Zukunft des Tissue Engineering. "Erkenntnisse aus der Entwicklungsbiologie werden uns helfen, Zellen dazu zu bringen, sich in den künstlichen Gerüsten so zu organisieren wie in einem echten Organ", glaubt die Bio-Ingenieurin Sangeeta Bhatia von der University of California, die versucht, mit einem photolithografischen Schichtverfahren eine Leber aus unterschiedlichen Zellmixturen aufzubauen.

Die Mobilisierung von Stammzellen durch Wachstumsfaktoren in einem dreidimensionalen implantierbaren Trägermaterial hätte den Vorteil, dass man "preiswertere Off-the-shelf-Produkte anbieten kann und nicht jedes Präparat eigenhändig mixen muss", erklärt Charité-Forscher Ringe. Bis derartige Verfahren tatsächlich funktionieren, müssen sich die Mediziner weiter mit Ersatzteilen aus Metall, Plastik und Silizium behelfen.

© Technology Review, Heise Zeitschriften Verlag, Hannover

[JoeUp]

SPIEGEL ONLINE - 27. September 2004, 10:26
URL: http://www.spiegel.de/wissenschaft/mensch/0,1518,320101,00.h…

Bio-Schrittmacher

Stammzellen lassen Herzen im Takt schlagen

Wenn das Herz den Takt verliert, könnten Stammzellen helfen. Mediziner haben in Experimenten mit Schweinen festgestellt, dass menschliche embryonale Stammzellen den Herzrhythmus positiv beeinflussen und künftig sogar als biologische Schrittmacher fungieren könnten.

Menschliche Stammzellen gelten manchen Medizinern als Hoffnungsträger Nummer eins bei der Therapie von Herzleiden: Nach Bypass-Operationen lösten sie bereits verblüffende Regenerationseffekte aus, und mehrfach wurde in Experimenten auch eine mögliche Rolle als biologischer Schrittmacher erprobt. Forscher aus Israel und den USA sind letzterem Ziel nun einen Schritt näher gekommen: Sie konnten zeigen, dass die Stammzellen strukturelle und elektromechanische Verbindungen mit dem Herzen bilden.

Die Wissenschaftler um Lior Gepstein vom Israelischen Institut für Technologie in Haifa hatten aus menschlichen embryonalen Stammzellen Herzmuskelzellen gezüchtet und sie anschließend in Herzmuskelgewebe von neugeborenen Ratten eingepflanzt. Nach einem Tag bewegten sich menschliches und Rattengewebe synchron: Die elektrischen Reize wurden zwischen beiden Gewebetypen übertragen. Auch eine Anregung mit Elektroden in nur einer Gewebeart aktivierte beide Gewebearten synchron, berichten die Forscher im Fachmagazin "Nature Biotechnology" (Online-Vorabveröffentlichung).

In einem weiteren Experiment spritzten die Forscher die Stammzellen in die linke Herzkammer von Schweinen. Bei den Tieren hatten sie zuvor den Herzschlag künstlich verlangsamt, indem sie die elektrische Reizweiterleitung im Herzen an der Schnittstelle zwischen dem Vorhof und den Herzkammern, dem so genannten Atrioventrikulär-Knoten, blockierten. Ein Defekt an dieser Stelle macht beim Menschen in vielen Fällen einen Herzschrittmacher notwendig.

Nach wenigen Tagen konnten die Mediziner per EKG Änderungen im Herzschlag der Schweine feststellen: Die eingespritzten Stammzellen korrigierten den künstlich verursachten Defekt teilweise. Mit elektrophysiologischen und pathologischen Untersuchungen bestätigten die Forscher, dass die Stammzellen die Verbesserung verursacht hatten.

Unklar ist jedoch, ob die Stammzellen die Herzaktivität direkt wieder herstellen oder die verbliebenen Herzmuskelzellen stimulieren. So könnten sie etwa bestimmte Substanzen ausschütten oder elektrische Reize übertragen, welche die ursprünglichen Herzzellen aktivieren. Die Wissenschaftler äußerten dennoch die Hoffnung, dass die Stammzellen eines Tages die Therapie mit herkömmlichen Herzschrittmachern ergänzen oder sogar als biologische Herzschrittmacher fungieren können.

[JoeUp]

CRYO-CELL Announces Corporate Relocation Strategic Capital Investment in State-of-the-Art Facility Positions CRYO-CELL in the Market and Ahead of Emerging Regulation

OLDSMAR, Fla., Dec 6, 2004 /PRNewswire-FirstCall via COMTEX/ -- CRYO-CELL
International, Inc. (OTC Bulletin Board: CCEL) (the "Company"), one of the
world`s oldest and largest private cord blood banks, announced today the
relocation of its corporate headquarters to a newly constructed, nearly
18,000-square-foot state-of-the-art current Good Manufacturing Practice and Good
Tissue Practice (cGMP/cGTP)-compliant facility. The highly secured,
technologically advanced facility is located less than five miles from the
Company`s previous site and is designed to support the expansive and growing
base of CRYO-CELL clients over the next ten years. This formal announcement
comes on the heels of record-setting revenue in the third quarter ended August
31, 2004 for the Company, which was established in 1989.

Food and Drug Administration (FDA) 21 CFR Part 1271, a new federal regulation
with an anticipated effective date of May 2005, requires human cellular and
tissue-based products to be manufactured in compliance with good tissue
practices (cGTPs). The Company`s new laboratory processing facility boasts a
class 10,000 clean-room and class 100 environments for the processing of cord
blood stem cells and other cellular tissues. In addition, the cellular products
cryogenic storage area has been designed as a "bunker", with enhanced provisions
for security, building fortification for environmental element protection and
back-up systems for operational redundancies.

"CRYO-CELL`s relocation to the new state-of-the-art facility comes at a time of
continuing momentum for the Company as reflected in our recent trend of
increased revenues, higher margins and solid earnings," said Mercedes Walton,
Chairman and interim CEO. "In yet another industry-leading development, we
believe that CRYO-CELL is the first private bank to process cord blood in a
technologically and operationally advanced cGMP/cGTP-compliant facility. The new
facility represents another major milestone towards CRYO-CELL`s vision of
innovative, standard-setting industry leadership driven by our commitment to
provide expectant families with a high-quality, superior- value service for the
preservation of their newborn`s cord blood stem cells. We believe that our new
facility positions CRYO-CELL well in the market, and ahead of emerging
regulation."

The newly constructed facility, which also houses the Company`s clinical
services, marketing and administrative operations, is designed and appointed to
accommodate a broad range of market-facing events such as client tours and open
houses, as well as clinician and expectant parent educational workshops.
Building public awareness for clinicians and families on the significant
benefits of umbilical cord blood stem cell preservation continues to be a major
initiative for CRYO-CELL.

As part of the relocation, nearly 75,000 client specimens were successfully
moved under tightly monitored and elaborately controlled conditions that
included police escort. Processing operations continued daily over the course of
the move.

The Company`s new address is: 700 Brooker Creek Blvd., Suite 1800, Oldsmar, FL
34677. The business phone number, [phone], and business fax, (813)
855-4745, both have changed. The toll-free number, [phone] for Clinical
Services, remains the same.

About CRYO-CELL International, Inc.

Based in Oldsmar, Florida, CRYO-CELL is the world`s largest U-Cord(R) stem cell
banking firm, offering high-quality cord blood preservation exclusively for the
benefit of newborn babies and possibly other members of their family. CRYO-CELL
is accredited by the American Association of Blood Banks (AABB).

CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol ... CCEL.
Expectant parents or healthcare professionals may call 1-800-STOR-CELL
(1-800-786-7235) or visit http://www.CRYO-CELL.com Forward-Looking Statement

[JoeUp]

CRYO-CELL Affiliate Wins Federal Grant for Cell Therapy Research

OLDSMAR, Fla., Dec 20, 2004 /PRNewswire-FirstCall via COMTEX/ -- CRYO-CELL
International, Inc. (OTC Bulletin Board: CCEL) (the "Company") announced today
that its affiliate, Saneron CCEL Therapeutics, Inc. ("Saneron CCEL"), has won a
federal grant for its novel approach to use cell therapy to treat spinal cord
injury.

Saneron CCEL was awarded a Small Business Innovation Research (SBIR) grant from
the National Institutes of Health (NIH) to develop Sertoli cells combined with
stem cells from cord blood for possible treatment of spinal cord injury. The
$150,000 grant is the latest in a series of six SBIR/STTR grants in which
Saneron CCEL and USF have collaborated together on their efforts to create
cellular therapies for neurological disorders.

In a recent announcement on this development, Cyndy Davis Sanberg, Ph.D., Vice
President for Research at Saneron CCEL and principal investigator of the grant,
commented, "We believe our studies will show that we can use natural human cells
instead of synthetic drugs to treat spinal cord injury, which would be
remarkable. This new study should add greatly to our mission of developing cord
blood stem cell therapies for repair of central nervous system injuries. Saneron
is extremely pleased that the NIH has recognized the enormous potential of these
cellular therapies by providing funding through these highly competitive grant
programs. Additional studies will be needed before moving forward to human
trials."

"CRYO-CELL is clearly encouraged that our affiliate, Saneron CCEL, has received
this important NIH grant," commented Mercedes Walton, CRYO-CELL`s Chairman and
interim CEO. "We believe that Saneron CCEL`s novel research, which utilizes
non-controversial cord blood stem cells, has significant promise for future
human therapeutic application. This is an important consideration for parents
who are weighing the benefits of banking their newborn`s cord blood.
Advancements in the development of cellular therapies for treatment of
neurological disorders, as well as for the treatment of numerous other
life-impacting diseases, are at the forefront of a new and exciting scientific
frontier." CRYO-CELL International, Inc. owns approximately 43% equity in
Saneron CCEL.

About CRYO-CELL International, Inc.

[JoeUp]

CRYO-CELL Announces Victory in Patent Litigation Delaware Court Finds No Infringement of PharmaStem`s Patents

OLDSMAR, Fla., Dec 16, 2004 /PRNewswire-FirstCall via COMTEX/ -- CRYO-CELL
International, Inc. (OTC Bulletin Board: CCEL) (the "Company") is pleased to
announce that on December 14, 2004, the United States District Court for the
District of Delaware issued an order entering a final judgment in favor of
CRYO-CELL International, Inc. ("CRYO-CELL") in patent infringement litigation
filed against it by PharmaStem Therapeutics, Inc. ("PharmaStem"). This order,
which can be viewed at
http://www.CRYO-CELL.com/resources/PharmaStem_121404_ruling.… , effectively
reverses every aspect of the October 2003 trial jury`s verdict of patent
infringement and damages award.

From an historical perspective, PharmaStem initiated patent litigation against
CRYO-CELL and other umbilical cord blood banking firms in February 2002. After a
trial in October 2003 before the Hon. Gregory M. Sleet and a jury, the parties
filed post-trial motions, which were decided by Judge Sleet in an order dated
September 15, 2004 (see CRYO-CELL`s press release dated September 20, 2004). At
that time, Judge Sleet granted the motion of CRYO-CELL and the other defendants
for entry of judgment as a matter of law ("JMOL") on infringement of
PharmaStem`s U.S. Patent No. 5,192,553 ("the `553 patent") reversing the jury`s
verdict on the `553 patent. In the September 15 order, the court denied the
defendants` motion for JMOL in their favor on infringement of U.S. Patent No.
5,004,681 ("the `681 patent"), but granted defendants` motion in the alternative
for a new trial on that issue.

CRYO-CELL subsequently filed a motion asking the Court to reconsider the denial
of JMOL on the `681 patent. The Court`s December 14, 2004 order granted that
motion, directing the entry of judgment in favor of CRYO-CELL and the other
defendants on the `681 patent. The effect of this order is that final judgment
has now been entered in favor of CRYO-CELL and the other defendants on
PharmaStem`s charges of infringement of both patents that were asserted in that
case, marking a final disposition of the case in CRYO-CELL`s favor. PharmaStem
has the right to appeal the decision to the United States Court of Appeals for
the Federal Circuit.

Mercedes Walton, CRYO-CELL`s Chairman and interim CEO, commented, "We are very
pleased that the Court has decided this case in the Company`s favor. We believe
that the Court`s decision has vindicated our long-standing position that
CRYO-CELL`s U-Cord(R) preservation business does not constitute infringement of
PharmaStem`s patents, and we continue to believe that these patents will
ultimately be rendered invalid. While we are certainly pleased with the final
rulings of the Delaware Court, we regret the confusion and disruption created by
this matter in the clinical and expectant parent communities during the course
of the litigation. This decision is a landmark step in clarifying the right of
CRYO-CELL to continue to serve the growing demand for the Company`s services of
preserving non-controversial umbilical cord blood stem cells."

About CRYO-CELL International, Inc.

[JoeUp]

U.s. deswegen stieg CCEL die letzten Wochen so
----------------------------------
http://www.nasdaq.com/asp/quotes_news.asp?cpath=20050104AC…

StemCells, Inc. Announces Filing of IND for Human Neural Stem Cell Transplant Treatment for Batten Disease

PALO ALTO, Calif.--(BUSINESS WIRE)--Jan. 4, 2005--

Phase I Clinical Trial at Stanford Would Be First-Ever Using Transplantation of Human Neural (Brain) Stem Cells

StemCells, Inc. (NASDAQ: STEM) today announced the filing of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA). Subject to approval, the Company plans to begin its first clinical investigation of its human neural (brain) stem cells (HuCNS-SC - StemCells` proprietary neural cell therapy product) in Batten disease. Batten disease is a rare, fatal genetic disorder that affects the central nervous system of children. If approved by the FDA, this would mark the first-ever FDA-approved clinical trial to use a purified composition of human neural stem cells as the potential therapeutic agent.

On approval of the IND by the FDA, the study will be conducted at Lucile Packard Children`s Hospital/Stanford University Medical Center (LPCH/SUMC) under the direction of Stephen L. Huhn, MD, FACS, FAAP, Chief of Pediatric Neurosurgery and Gregory M. Enns, MB, ChB, Assistant Professor and Director, Biochemical Genetics Program, Division of Medical Genetics.

"This is truly a significant milestone, not only for StemCells, Inc., but also for all scientists who have been seeking to evaluate possible therapies for neural and neurodegenerative diseases," said Martin McGlynn, chief executive officer of StemCells, Inc. "Our pre-clinical research has shown great promise and this filing is an essential step in discovering how to translate those pre-clinical results into treatment of human victims of terrible disorders like Batten disease and other neurodegenerative lysosomal storage diseases. It is only a first step, though - this is a Phase I, or safety, trial, from which we hope to learn about the behavior of the cells when they are transplanted into a human recipient. There will be many other steps to take before we arrive. But it is our hope that transplantation of human neural stem cells could prove to be a platform technology for a wide range of conditions for which there is now no reliable and effective treatment."

"We are looking forward to working with the scientists at StemCells in this historic clinical trial," said Dr. Huhn, at Stanford University School of Medicine. "We are exploring new territory, which dictates that we proceed with due caution. I believe, however, that our path has been determined by rigorous research and a well-designed protocol. Physicians have been essentially helpless to assist children suffering from Batten`s, and all of us involved in this trial are hoping it will lead to a future in which we will have an efficient treatment, or even a cure. As a pediatric neurosurgeon, I am particularly excited about this avenue of research."

About the Clinical Trial

The proposed Phase I trial is designed to investigate the safety of HuCNS-SC in the treatment of infantile and late-infantile neuronal ceroid lipofuscinosis (NCL), the most severe forms of a group of disorders commonly referred to as Batten disease. The trial will be an open label study of two dose levels involving three subjects in each of two cohorts. The primary objective of the trial will be to measure the safety of HuCNS-SC. However, the trial will also evaluate HuCNS-SC`s ability to affect the progression of the disease. The patient/subject evaluation will be up to one year post HuCNS-SC transplantation. Candidates from anywhere in the world will be referred by their primary physicians to the Co-principal Investigators at LPCH/SUMC. Potential patients will be tested for eligibility and then evaluated for baseline disease status prior to transplantation. The Company is committed to following the effects of this therapy long-term, so potential trial patients will also be asked to commit to a four year follow-up study.

About Batten Disease

Batten disease is named after the British pediatrician who first described the juvenile form of NCL in 1903. It is also known as Spielmeyer-Vogt-Sjogren-Batten disease. The name is now commonly used to encompass all three forms of NCL. The forms of NCL are classified by age of onset (infantile, late infantile and juvenile) but are more precisely classifiable in terms of the specific enzyme causing the disease. They all have the same basic cause - lack of a lysosomal enzyme - and similar progression and outcome, but are all genetically different. Children with Batten disease suffer seizures, progressive loss of motor skills, sight and mental capacity, eventually becoming blind, bedridden and unable to communicate. Today, Batten disease is always fatal.

In two sub-types of the NCLs - infantile and late infantile or, more technically, CLN1 and CLN2 - normally secreted housekeeping lysosomal enzymes are either defective or missing altogether, as a result of gene mutations. Lack of either enzyme causes a buildup of lipofuscin (aggregates of lipids and proteins) primarily in the brain and leads to neuronal cell loss.

In the proposed clinical trial, HuCNS-SC will be transplanted in the CLN1 and CLN2 patients in part to determine if the transplanted cells secrete the missing lysosomal enzymes in the brains of affected individuals. HuCNS-SC have been shown to produce both PPT1 and TPP-I enzymes, providing a scientific justification for enzyme replacement and cellular rescue in this indication. In preclinical models of PPT1 deficiency, the corresponding enzyme activity increases with time after transplantation.

About HuCNS-SC and the Clinical Trial

StemCell`s human central nervous system stem cells (HuCNS-SC) are a somatic cell therapy product consisting of neural cells prepared under controlled conditions. Neural stem cells, a rare subset of brain cells, are isolated from the human fetal brain, purified, propagated, and tested; they are then frozen in cell banks from which HuCNS-SC doses can be prepared.

NCLs are lysosomal storage disorders brought on by inherited genetic mutations in CLN1 gene, which codes for palmitoyl-protein thioesterase 1 (PPT1) and in the CLN2 gene, which codes for tripeptidyl peptidase I (TPP-I). The consequence of these mutations is the accumulation of lipofuscin-like fluorescent inclusions in various cell types that eventually lead to cell degeneration. Presumably, non-degraded lysosomal substrates accumulate to the point where they interfere with normal cellular and tissue function and lead to the pathological manifestations of the related disease. To correct the major defect in these subjects, enzyme would have to be available in the brain where it can be taken up by the enzyme deficient cells. A property of HuCNS-SC is production of both PPT1 and TPP-I enzymes. Thus, placement of HuCNS-SC in appropriate places in the brain has the prospect of replacing the missing enzyme.

About StemCells, Inc.

StemCells, Inc. is a development stage biotechnology company focused on the discovery, development and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. The Company`s stem cell programs seek to repair or repopulate neural or other tissue that has been damaged or lost as a result of disease or injury. StemCells is the first company to directly identify and isolate human neural stem cells from normal brain tissue. These stem cells are expandable into cell banks for therapeutic use, which demonstrates the feasibility of using normal, non-genetically modified cells as cell-based therapies. StemCells is the only publicly traded company solely focused on stem cell research and development and has more than 40 U.S. and 100 non-U.S. patents, as well as 100 patent applications pending worldwide. Further information about the Company is available on its web site at: www.stemcellsinc.com.

Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among other things, the future business operations of StemCells, Inc. ("the Company"). The forward-looking statements speak only as of the date of this news release. StemCells does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management`s current views and are based on certain assumptions that may or may not ultimately prove valid. The Company`s actual results may vary materially from those contemplated in the forward-looking statements due to risks and uncertainties to which the Company is subject, including uncertainties regarding the Company`s ability to obtain the capital resources needed to continue its current research and development operations and to conduct the research, preclinical development and clinical trials necessary for regulatory approvals; the uncertainty whether the FDA will approve the IND and permit the Company to proceed to clinical testing; the uncertainty regarding the outcome of the Phase I clinical trial and any other trials the Company may conduct in the future; the uncertainty regarding the validity and enforceability of issued patents; the uncertainty whether any products that may be generated in the Company`s stem cell programs will prove clinically effective and not cause tumors or other side effects; the uncertainty whether the Company will achieve revenues from product sales or become profitable; uncertainties regarding the Company`s obligations in regard to its former encapsulated cell therapy facilities in Rhode Island; and other factors that are described in Exhibit 99 to the Company`s Annual Report on Form 10-K titled "Cautionary Factors Relevant to Forward-Looking Statements."

CONTACT: StemCells, Inc.Judi Lum, 650-475-3100
or
Schwartz Communications, Inc.
Media:
781-684-0770 or 415-512-0770
[e-mail]

SOURCE: StemCells, Inc.

[JoeUp]

[JoeUp]

[JoeUp]

Etwas älter, aber ......

http://aktien.onvista.de/empfehlungen.html?ID_OSI=93987#news

02.11.2004 14:33:31 (HOT STOCKS INVESTOR)
Cryo-Cell ein Kauf


Die Aktienexperten von "Hot Stocks Investor" unterstreichen ihre Kaufempfehlung für die Aktie von Cryo-Cell (ISIN US2288951088/ WKN 923368). Die erfreulichen Quartalszahlen seien im Markt zunächst etwas reserviert aufgenommen worden. Die Umsatzzuwächse würden insbesondere aus Preiserhöhungen resultieren. In Tierversuchen habe nun die Tochtergesellschaft Saneron CCEL viel versprechende Ergebnisse beim therapeutischen Einsatz von Stammzellen bei Schlaganfällen berichten können. Cryo-Cells Angebot bestehe darin, bei Neugeborenen aus dem Nabelschnurblut Stammzellen zu isolieren und individuell für einen möglichen späteren therapeutischen Einsatz für genau diesen Patienten zu archivieren. Nach dem wie erwartet verlaufenen Sommerloch stufen die Experten von "Hot Stocks Investor" die Cryo-Cell-Aktie wieder als klaren Favoriten ein und unterstreichen ihre Kaufempfehlung. Derzeit bewege sich der Titel in einer engen Tradingrange mit einem oberen Band bei 3 US-Dollar. Das Überwinden dieser Hürde sei als finales Startsignal zu interpretieren.
Quelle: AKTIENCHECK.DE

[JoeUp]

Umbilical Cord Blood Stem Cells Utilized by USF Researchers to Treat Heart Attack in Animals

OLDSMAR, Fla., Jan 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- Researchers
from the University of South Florida ("USF") and James A. Haley Veterans
Hospital have reported in the journal "Cell Transplantation" that stem cells
from umbilical cord blood effectively treated heart attacks in an animal study.
Injected into rats` hearts after heart attack, human umbilical cord blood cells
were shown to greatly reduce the size of heart damage and restored pumping
function to near normal.

The USF study was supported by the American Heart Association, the Veterans
Administration, a Florida biomedical research grant and Saneron CCEL
Therapeutics, Inc., an affiliate of CRYO-CELL International, Inc. (OTC Bulletin
Board: CCEL). Some study authors are affiliated with Saneron and are
co-inventors on related patent applications by USF.

Paul Sanberg, Ph.D., D.Sc., co-author of the study, commented, "Cord blood stem
cells may be more amenable to cardiac repair than those taken from other sources
like bone marrow or skeletal muscle. In addition, cord blood is readily
accessible, easy to use, and non-controversial when compared to embryonic stem
cells."

"Results from this recent study demonstrate that human umbilical cord blood
cells have regenerative cardiac effects in animal studies," stated Mercedes
Walton, CRYO-CELL`s Chairman and interim CEO. "In view of the widespread
prevalence of heart disease, cell therapies may have future human application,
which could actually strengthen cardiac muscle, thereby restoring cardiac
function. Although this research is preliminary and the reported trials are
pre-clinical, early indications are very promising and its potential represents
a compelling reason for parents to consider banking their newborn`s cord blood."
CRYO-CELL International, Inc. owns approximately 43% equity in Saneron CCEL.

About CRYO-CELL International, Inc.

Based in Oldsmar, Florida, CRYO-CELL is the world`s largest U-Cord(R) stem cell
banking firm, offering high-quality cord blood preservation exclusively for the
benefit of newborn babies and possibly other members of their family. CRYO-CELL
is accredited by the American Association of Blood Banks (AABB). CRYO-CELL is a
publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents
or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit
http://www.CRYO-CELL.com
About Saneron CCEL Therapeutics, Inc.

Saneron CCEL Therapeutics, Inc. is a biotechnology R&D startup company focused
on cell therapy for the early intervention and treatment of several devastating
or deadly diseases, which currently lack adequate treatment options. Saneron
CCEL, located at the USF Center for Entrepreneurship in Tampa, FL, was created
by the merger of Saneron Therapeutics, Inc. and CCEL Bio-Therapies, Inc.,
formerly a wholly owned subsidiary of CRYO-CELL International, Inc. Saneron CCEL
is committed to providing readily available, non-controversial stem cells for
cellular therapies and has exclusively licensed patented technology relating to
our platform technology of U-CORD-CELL(TM) -- umbilical cord blood, and
SERT-CELL(TM) -- Sertoli cells.

Forward-Looking Statement

[JoeUp]

Nr. 1 vom 17. Januar 2005 HOT STOCKS INVESTOR HOT STOCKS INVESTOR

Die Krise um die als problematisch eingestuften Cox-2-Inhibitoren macht aus
Sicht vieler Analysten deutlich, dass die Blockbuster-Politik im Pharmabereich
vor einer möglichen Ablösung steht! Die in der Schusslinie stehenden PFIZER
und MERCK gelten als die führenden Protagonisten dieser Politik, deren Schattenseite
mit milliardenschweren Schadenersatzklagen bei Pannen jetzt zu Tage tritt.
Die Konkurrenz um ABBOT, WYETH oder BRISTOL-MYERS hat hier schon
längst andere Akzente gesetzt und sich auf weniger ?grosse? Präparate mit einem
auch entsprechend geringeren Risiko fokussiert. Mit Schadenfreude wird man dort
das angehende Schlachtfest um die beiden Grossen kaum begleiten, wohl aber mit
Sicherheit eigene Konsequenzen bei der eigenen Strategieformulierung ziehen. Vor
allem für MERCK muss die Pleite als besonders schmerzlich gelten, weil man dort
mit Arcoxia ein weiteres Schmerzpräparat mit Blockbusterpotenzial in der Pipeline
wähnte ? das allerdings leider ebenfalls ein Cox-2-Hemmer ist, auf dessen Zulassung
durch die FDA heute niemand mehr einen Pfifferling verwetten möchte. Die nun aufbrechende strategische Neuausrichtung
in der gesamten Branche kann aber nichts anderes heissen, als dass die Pharmaunternehmen dringend eine Vielzahl
an neuen Präparatideen benötigen ? zur Not durch auch durch Käufe und Übernahmen von forschungsstarken Biotechfirmen!
Und genau deshalb fängt es hier inzwischen an zu kochen:

Den Anfang machten CRYO CELL, die sich mit einer Mitte Dezember
gezündeten Kursexplosion auf neue Mehrjahreshochs von USD 7 zu unseren
Empfehlungskursen von Anfang November glatt verdreifachten! Sie
erinnern sich: Mit dem Ergebnis der Präsidentschaftswahlen im November
schien das Schicksal der Stammzellenforscher zunächst besiegelt. Voll Sorge
über massive Restriktionen seitens der bestätigten konservativen Administration
zog sich der Markt aus den Titeln dieses Sektors zurück. Vor allem bei CRYO
CELL klar zu Unrecht, wie wir bereits im November konstatierten, denn das
Business-Modell dieses Unternehmens sieht sich von ethischen Bedenken
schon aus Prinzip nicht betroffen, da man selbst kaum solche Forschung
betreibt und sich vor allem auf die kommerzielle Archivierung von individuellen
Stammzellenlinien konzentriert. Nicht nur die wachsenden Kundenzahlen
von CRYO CELL belegen aber, dass mittelfristig ein Siegeszug dieser Forschungsdisziplin kaum noch aufzuhalten sein
dürfte. Gerade auch in den USA zeigt die praktische Politik da längst ganz andere Signale, als die Fernsehpredigten vor
dem Wahltermin Glauben machen wollten: So ging ohne grossen Aufschrei die Ankündigung des Staates Kalifornien
über die Bühne, ein USD 3 Mrd. schweres Stammzellenforschungsprogramm auf den Weg zu bringen! Noch drastischer:
Auch die als extrem konservativ in Sachen Stammzellenforschung
geltende Bundespolitik in Washington zeigte
sich zuletzt beweglicher, als manche geglaubt hatten! Es
kommt in der Administration Bush eben immer nur auf das
richtige Stichwort an und wenn dieses ?innere Sicherheit? lautet,
werden auch vermeintliche Tabus verhandelbar. So hat das
Verteidigungsministerium ein Förderprogramm für Stammzellenforschung
aufgelegt im Hinblick auf den Einsatz im
Bereich Bio-Defense.

Konsequenz: Mit AASTROM BIO
und STEMCELLS schossen in den letzten Tagen jetzt auch
die klassischen Forschungstitel im Stammzellensektor durch
die Decke. Dieses Terrain ist aber weitaus problematischer,
weil hier die immer wieder neu diskutierten Ethikregeln eine
ganz klare Begrenzung der Forschungsmöglichkeiten setzen können. Entsprechend schwer kalkulierbar bleibt hier das
Risikoterrain, was diese Titel heisser macht als beispielsweise CRYO CELL. Mutige spekulative Trader, die nah am Markt
operieren können, lassen sich aber die Chance nicht entgehen, mit Tradingpositionen auch bei diesen beiden Werten dabei
zu sein. Wie wir hören, denken einige Länder an mögliche Lockerungen der Forschungsvorschriften für Stammzellenuntersuchungen,
was es diesen Unternehmen erlauben könnte, entsprechende Forschungsquartiere zu beziehen! (AASTROM
BIO WKN 905 286, Kurs aktuell EUR 1.95, STEMCELLS WKN 889 118, Kurs aktuell EUR 3.95).

[meislo]

Amgen: Gewinn durch ViaCell-IPO



ViaCell, ein auf Stammzellenforschung spezialisiertes Unternehmen ist heute in den USA an die Börse gegangen. Das Unternehmen brachte 7,5 Millionen Titel zu einem Startkurs von 7 Dollar auf den Markt.
Inzwischen konnten sich die Titel um satte 31,86 Prozent auf 9,23 Dollar nach oben arbeiten. Damit ist rein rechnerisch nun auch der Großaktionär Amgen in der Gewinnzone. Der Konzern hatte 2003 20 Millionen Aktien von ViaCell für 8 Dollar pro Aktie erworben. Viacell widmet sich überwiegend der Stammzellenforschung. Daneben lagert das Unternehmen gegen Geld Nabelschnurblut von Neugeborenen für mögliche spätere therapeutische Zwecke ein.
Amgen können sich aktuell um 0,14 Prozent auf 62,65 Dollar verbessern.

[JoeUp]

was ist die Stammzelle: hier eine gute Darstellung dessen
(dank meislo)

http://www.biotech-world.de/archiv/letter/092002.pdf

*Aber meislo, beschränken wir diesen Thread bitte AUSSCHLIESSLICH auf CCEL, sonst findet man vor lauter Stammzellenfirmen die CCEL nicht wieder, danke.

[JoeUp]

ich warte immer noch auf das Q4 Reporting und das Jahresergebnis 2004, da das Wirtschaftsjahr bereits am 30.11.2004 endete.

Hier mal eine Übersicht über die Investoren in CCEL:

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=00…

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=00…

[JoeUp]

Cryo-Cell International, Inc. Reports Results for Fiscal 2004 Company Reports Net Income, Increased Revenues, Higher Gross Margins, and Strong Cash Position Solid Financial Performance Continues as Company Proceeds With Strategic Plan

CLEARWATER, Fla., Feb 11, 2005 /PRNewswire-FirstCall via COMTEX/ -- CRYO-CELL
International, Inc. (OTC Bulletin Board Symbol: CCEL)(the "Company") today
announced revenues of approximately $12.2 million for the fiscal year ended
November 30, 2004, compared to approximately $7.5 million for fiscal 2003. The
62% revenue increase over 2003 period is primarily attributable to new clients
and the effects of successfully implemented price increases during 2004 for
newly enrolling clients.

Net income in fiscal 2004 was approximately $2.8 million, or $0.25 per common
share -- basic, compared to a net loss of approximately $7.5 million, or ($0.66)
per common share -- basic, in fiscal 2003. The net income in 2004, compared to
the net loss in 2003, was due in part to a $4.1 million increase in gross
profits compared to 2003 levels and a reduction of $1.7 million, or 21% in
marketing, general and administrative expenses. Net income in 2004 also included
approximately $1.1 million from the reversal of an accrual of expense in fiscal
2003 relating to the PharmaStem litigation. That accrual had increased the net
loss in fiscal 2003 by $1.1 million. The reversal of the accrual resulted from a
favorable ruling by the Court on post-trial motions in that case during 2004.
Other items that contributed to the net loss in fiscal 2003 that are not
included in the results of fiscal 2004 include asset impairment charges of
approximately $2 million. The impairment charges in 2003 included the reduction
in value of investments in subsidiaries and affiliates and charges related to
the decision to discontinue further investment in and utilization of the
Company`s proprietary storage technology. In addition, losses from discontinued
operations of Stem Cell Preservation Technologies, Inc., a discontinued
subsidiary, were approximately $93,000 in 2004 compared with $689,000 in 2003.

The Company also recognized approximately $550,000 in other income in 2004,
compared to approximately $211,000 in 2003. Other income principally consisted
of income recognized on the sale of license agreements, royalty income earned on
the subsequent processing and storage of specimens in geographic areas, where
the Company has licensing agreements, and from the sale of sub-licenses by
licensees.

The Company`s gross margin increased to 74% of revenue in 2004 from 65% in 2003.
The gross margin improvement is a result of the 62% increase in revenues, as
described above, combined with an increase of only 20% in cost of sales. As of
November 30, 2004, the Company had approximately $6.0 million in available cash,
cash equivalents and marketable securities and no long-term debt. As a result of
the Court`s favorable ruling in the PharmaStem litigation, the Company recovered
approximately $958,000 in cash during the fourth quarter 2004 that was being
held in an escrow account in connection with the original jury verdict. During
fiscal 2004, the Company invested approximately $686,000 of capital in the
build-out of its new facility, which was funded entirely from cash flow from
operations.

"We are very pleased with CRYO-CELL`s continuing solid performance throughout
2004," commented Mercedes Walton, Chairman and interim CEO. "The Company
achieved significant operational milestones as reflected by increased revenues,
decreased expense, higher margins, positive operating income and enhanced
shareholder value. From a strategic perspective, CRYO-CELL made substantial
progress in 2004 towards reaching resolution on a majority of outstanding legacy
issues, along with launching key alliances that we believe will accelerate our
industry leadership moving forward."

In addition to successfully repositioning CRYO-CELL`s core service which
included a strategic pricing increase, the Company was awarded category
exclusivity to participate in a highly targeted marketing initiative with
American Baby and Prenate Elite(TM), America`s most widely prescribed prenatal
vitamin. CRYO-CELL also joined some of America`s leading companies in teaming up
with Upromise(R), Inc. to become the first and only private cord blood bank to
participate in this industry-leading college savings service in which the
Company gives clients money back for college. CRYO-CELL also signed a License
and Royalty Agreement with Asia CRYO-CELL Private Limited, a newly formed Indian
company that is well capitalized and has demonstrated skills, knowledge and
professional networks necessary to successfully launch the U-Cord(R) program in
India, with approximately 20 million births per year representing one of the
largest birth markets in the world.

In another major milestone, CRYO-CELL relocated its corporate headquarters in
November 2004 to a newly constructed, nearly 18,000 square-foot, state-of-
the-art, current Good Manufacturing Practice and Good Tissue Practice
(cGMP/cGTP)-compliant facility. The highly secured, technologically advanced
facility is designed to support the expansive and growing base of currently more
than 75,000 CRYO-CELL clients, over the next ten years. The Company`s new
laboratory processing facility boasts a class 10,000 clean room and class 100
environments for the processing of cord blood stem cells and other cellular
tissues. The Company believes that CRYO-CELL is the first private bank to
process cord blood in a technologically and operationally advanced
(cGMP/cGTP)-compliant facility, which positions CRYO-CELL well in the market and
ahead of emerging regulation.

"Moving forward, CRYO-CELL expects to build on our strong performance,
formidable progress and continuing momentum of 2004," Ms. Walton continued.
"With a strong cash position and no long-term debt, we anticipate that continued
revenue growth and further advancements with our strategic plan and business
goals will favorably impact earnings in the coming periods."

About CRYO-CELL International, Inc.

Based in Oldsmar, Florida, CRYO-CELL is the world`s largest U-Cord(R) stem cell
banking firm, offering high-quality cord blood preservation exclusively for the
benefit of newborn babies and possibly other members of their family. With over
75,000 clients, CRYO-CELL is accredited by the American Association of Blood
Banks (AABB) and operates in a newly constructed state-of-the-art current Good
Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)- compliant facility.

CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol CCEL.
Expectant parents or healthcare professionals may call 1-800-STOR-CELL
(1-800-786-7235) or visit http://www.CRYO-CELL.com
Forward-Looking Statement

Statements wherein the terms "believes," "intends," "projects" or "expects" as
used are intended to reflect "forward-looking statements" of the Company. The
information contained herein is subject to various risks, uncertainties and
other factors that could cause actual results to differ materially from the
results anticipated in such forward-looking statements or paragraphs, many of
which are outside the control of the Company. These uncertainties and other
factors include any adverse effect or limitations caused by recent increases in
government regulation of stem cell storage facilities; any increased competition
in our business; any decrease or slowdown in the number of people seeking to
store umbilical cord blood stem cells or decrease in the number of people paying
annual storage fees; any adverse impacts on our revenue or operating margins due
to the costs associated with increased growth in our business, including the
possibility of unanticipated costs relating to the operation of our new
facility; any technological breakthrough or medical breakthrough that would
render the Company`s business of stem cell preservation obsolete; any material
failure or malfunction in our storage facilities; any natural disaster such as a
tornado, other disaster (fire) or act of terrorism that adversely affects stored
specimens; the costs associated with defending or prosecuting litigation matters
and any material adverse result from such matters; decreases in asset
valuations; any continued negative effect from adverse publicity in the past
year regarding the Company`s business operations; any negative consequences
resulting from deriving, shipping and storing specimens at a second location;
any negative effect from the filed class action shareholder lawsuits; and other
risks and uncertainties. The foregoing list is not exhaustive, and the Company
disclaims any obligations to subsequently revise any forward-looking statements
to reflect events or circumstances after the date of such statements. Readers
should carefully review the risk factors described in other documents the
Company files from time to time with the Securities and Exchange Commission,
including the most recent Annual Report on Form 10-KSB, Quarterly Reports on
Form 10-QSB and any Current Reports on Form 8-K filed by the Company.

SOURCE CRYO-CELL International, Inc.

[JoeUp]

CRYO-CELL International, Inc. Reports Results for First Quarter 2005

Company Reports Net Income, Increased Revenues, and Strong Cash Position

Solid Financial Performance Continues As Company Proceeds With Strategic Plan

OLDSMAR, Fla., April 5 /PRNewswire-FirstCall/ -- CRYO-CELL International, Inc. (OTC Bulletin Board Symbol: CCEL) (the "Company") today announced consolidated revenues of approximately $3.3 million for the first quarter ended February 28, 2005, compared to approximately $2.6 million for the first quarter ended February 29, 2004. The 27% revenue increase over the same 2004 period is primarily attributable to the effects of successfully implemented price increases during 2003 and 2004 for newly enrolling clients, as well as the overall increase in customer base over the prior year. These price increases began to have a positive impact on revenues in the third quarter 2003 and have continued through the first quarter of 2005.

Net income in the first quarter of 2005 was approximately $179,000, or $.02 per common share - basic, compared to net income of approximately $214,000, or $.02 per common share - basic, in the first quarter 2004. The Company`s operating income in the first quarter of 2005 was approximately $267,000 compared to operating income of approximately $272,000 in the first quarter 2004. The slight 2% decrease in operating income year-over-year is attributable to a 36% increase in cost of sales and a 32% increase in marketing, general and administrative expenses in the 2005 period versus the 2004 period, partially offset by a 27% increase in revenue, as described earlier. The increase in expenses is a result of the Company`s strategic plan to build the infrastructure to enhance existing production procedures and quality systems in the processing of cord blood specimens at the Company`s new state-of-the-art, current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility in Oldsmar, Florida. The Company also deployed a new customer database, new network infrastructure, and implemented plans to expand sales and marketing initiatives. Despite the investments in the new facility, operating infrastructure and information systems, the Company`s cash increased approximately $377,000 over the fourth quarter 2004. As of February 28, 2005, the Company had approximately $6.3 million in available cash, cash equivalents, marketable securities and other investments, which represent a 75% increase over the first quarter of 2004, and no long-term debt. First quarter 2005 enrollments, an indicator of future revenue levels, increased approximately 20% over fourth quarter 2004 levels.

The Company also recognized approximately $105,000 in licensee income in the first quarter of 2005, compared to approximately $77,000 in the first quarter 2004. Licensee income principally consisted of income recognized from royalty income earned on the subsequent processing and storage of specimens in geographic areas where the Company has licensing agreements and from the sale of sub-licenses by licensees.

"We are pleased that CRYO-CELL has reported a profitable first quarter of 2005. The Company continues to make significant progress in accordance with the stated priorities of our strategic plan to accelerate growth and to achieve industry-leading technological and operational excellence, with a keen focus on process automation," said Mercedes Walton, CRYO-CELL`s Chairman and interim Chief Executive Officer. "The Company`s substantial investment in our new state-of-the-art facility, advanced systems and operational infrastructure has established CRYO-CELL in a formidable competitive position, well ahead of emerging regulatory standards that will have industry-wide impact."

"Notwithstanding expected quarterly fluctuations in net income due to increased expense associated with operating a cGMP/cGTP-compliant facility, in addition to planned increases in marketing and sales spending," Ms. Walton continued, "we anticipate that our strategic investment in our business, combined with our sustainable success in operational execution, will continue to impact unit growth and profitability."

About CRYO-CELL International, Inc.

Based in Oldsmar, Florida, CRYO-CELL is the world`s largest U-Cord(R) stem cell banking firm, offering high-quality cord blood preservation exclusively for the benefit of newborn babies and possibly other members of their family. With over 75,000 clients, CRYO-CELL is accredited by the American Association of Blood Banks (AABB) and operates in a newly constructed state-of-the-art current Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)- compliant facility.

CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol ... CCEL. Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-786-7235) or visit http://www.CRYO-CELL.com .

Forward-Looking Statement

Statements wherein the terms "believes," "intends," "projects" or "expects" as used are intended to reflect "forward-looking statements" of the Company. The information contained herein is subject to various risks, uncertainties and other factors that could cause actual results to differ materially from the results anticipated in such forward-looking statements or paragraphs, many of which are outside the control of the Company. These uncertainties and other factors include any adverse effect or limitations caused by recent increases in government regulation of stem cell storage facilities; any increased competition in our business; any decrease or slowdown in the number of people seeking to store umbilical cord blood stem cells or decrease in the number of people paying annual storage fees; any adverse impacts on our revenue or operating margins due to the costs associated with increased growth in our business, including the possibility of unanticipated costs relating to the operation of our new facility; any technological breakthrough or medical breakthrough that would render the Company`s business of stem cell preservation obsolete; any material failure or malfunction in our storage facilities; any natural disaster such as a tornado, other disaster (fire) or act of terrorism that adversely affects stored specimens; the costs associated with defending or prosecuting litigation matters and any material adverse result from such matters; decreases in asset valuations; any continued negative effect from adverse publicity in the past year regarding the Company`s business operations; any negative consequences resulting from deriving, shipping and storing specimens at a second location; and other risks and uncertainties. The foregoing list is not exhaustive, and the Company disclaims any obligations to subsequently revise any forward- looking statements to reflect events or circumstances after the date of such statements. Readers should carefully review the risk factors described in other documents the Company files from time to time with the Securities and Exchange Commission, including the most recent Annual Report on Form 10-KSB, Quarterly Reports on Form 10-QSB and any Current Reports on Form 8-K filed by the Company.

SOURCE CRYO-CELL International, Inc.
-0- 04/05/2005
/CONTACT: Todd Atenhan of CRYO-CELL International, Inc., [phone],
or fax, [phone], or [e-mail]/
/Web site: http://www.cryo-cell.com /
(CCEL)

CO: CRYO-CELL International, Inc.
ST: Florida
IN: MTC OTC BIO HEA
SU: ERN

AC-MD
-- FLTU014 --
2843 04/05/200508:55 EDThttp://www.prnewswire.com

[JoeUp]

CRYO-CELL Comments on Proposed Government Initiative to Fund National Public Cord Blood Bank Recommendation Could Potentially Have Positive Impact on the Company

OLDSMAR, Fla., April 21, 2005 /PRNewswire-FirstCall via COMTEX/ -- CRYO-CELL
International, Inc. (OTC Bulletin Board Symbol: CCEL) (the "Company") today
announced its endorsement of proposed federal legislation to create a National
Cord Blood Stem Cell Program. The Institute of Medicine (IOM), an agency of The
National Academies, recently released a report supporting federal funding to
build an inventory of high-quality cord blood units for use in stem cell
transplantation. If enacted, funding could provide for upwards of 100,000
additional units of donated cord blood to be potentially used in allogeneic
(non-family related) transplants. The IOM report also recommends establishment
of a policy board to adopt more rigorous quality standards with respect to cord
blood products.

CRYO-CELL believes that the IOM report serves to underscore a simple message
that the Company has delivered to clinicians and expectant parents for well over
a decade: "cord blood stem cells save lives." The Company`s 14-year-old business
of preserving non-controversial stem cells for family use has grown dramatically
over the past five years. CRYO-CELL currently stores nearly 80,000 family-owned
samples.

Because a growing but still relatively small number of families participate in a
family banking service, CRYO-CELL recognizes the potential public value that a
larger supply of stem cells could provide. The Company`s educational materials
list public donation as an alternative to private family banking, while
reminding expectant parents that once donated, their newborn`s stem cells may
not be available for their family should the need arise. Throughout the medical
community, it is historically well accepted that matched family stem cells, if
available, are often preferable to cells from an unrelated donor because of
fewer transplant complications.

CRYO-CELL also advocates the expansion of regulation/oversight that the IOM
report promotes for the safety for transplant recipients. The Company believes
it is the first private cord blood bank to operate its own Good Manufacturing
(cGMP) and Good Tissue Practice (cGTP) compliant processing and storage
facility, which positions CRYO-CELL well ahead of competition and anticipated
FDA regulations.

As a market leader among private cord blood banks, CRYO-CELL believes it may be
in a position to contribute to the development of quality and licensing
standards that may be established should the $10 million congressional mandate
to set up a nationwide cord blood stem-cell bank come to fruition. In recent
months, CRYO-CELL has been host to government officials seeking operational
insights from a private state-of-the art facility.

"The Company believes that the new government initiative could potentially
impact CRYO-CELL on many positive dimensions. With the emergence of tightened
federal regulation of private cord banks, barriers to entry in this industry
will likely be raised and consumers could be assured of doing business with only
those companies who meet the most rigorous and superior quality standards,"
commented Mercedes Walton, Chairman and interim CEO.

"Whatever the outcome of the new government initiative," Ms. Walton continued,
"CRYO-CELL expects that our strong and expanding client base, along with our
demonstrated revenue growth over the last five consecutive quarters, will serve
as a strong foundation for the Company`s future growth."

About CRYO-CELL International, Inc.

Based in Oldsmar, Florida, CRYO-CELL is the world`s largest U-Cord(R) stem cell
banking firm, offering high-quality cord blood preservation exclusively for the
benefit of newborn babies and possibly other members of their family. With
nearly 80,000 clients, CRYO-CELL is accredited by the AABB and operates in a
newly constructed state-of-the-art current Good Manufacturing Practice and Good
Tissue Practice (cGMP/cGTP) compliant facility.

CRYO-CELL is a publicly traded company. OTC Bulletin Board Symbol CCEL.
Expectant parents or healthcare professionals may call 1-800-STOR-CELL (1-800-
786-7235) or visit http://www.CRYO-CELL.com
Forward-Looking Statement